Background: Biased agonism is an incompletely understood phenomenon describing the unequal activation of different signal transduction pathways by a G protein-coupled receptor (GPCR). Results: A cell-free approach using GPCR-transducer fusion proteins (G-protein or ␤-arrestin) quantifies signaling in vitro to elucidate the molecular basis of biased agonism. Conclusion: Differences in ligand-receptor-transducer coupling account for biased agonism in cells. Significance: Biased agonism is a bona fide molecular property of GPCR ligands.
G protein-coupled receptors (GPCRs), 3 also known as 7 transmembrane spanning receptors or 7TMRs, are attractive therapeutic targets as they regulate the majority of physiological processes in humans by binding and transducing signals from a wide variety of endogenous and exogenous ligands. Ligands that bind and activate GPCRs, termed agonists, initiate highly conserved signaling and regulatory cascades. These are marked by receptor interactions with heterotrimeric G proteins which promote second messenger generation, G proteincoupled receptor kinases (GRKs) which phosphorylate the activated receptors, and ␤-arrestins (␤arrs) which bind to the phosphorylated receptors and attenuate signaling (1) .
Recently, however, two interrelated and dramatic paradigm shifts have changed our understanding of how GPCRs function. In the first it has been appreciated that interaction of the receptors with ␤arr1 and ␤arr2 leads not only to desensitization of their G protein-mediated actions and endocytosis via clathrincoated pits but also to activation of numerous recently appreciated signaling pathways by virtue of their ability to serve as multifunctional scaffolds and adaptors (2) (3) (4) . In fact this appears to be a general mechanism through which ␤arrs interact with numerous signaling molecules to coordinate a wide variety of cellular processes (5) .
In the second paradigm shift, the "two state" model of receptor action that postulates an inactive (R) conformation of the receptor in equilibrium with a unitary active (R*) conformation has given way to models in which receptors exist in multiple ligand-specific active (R* n ) conformations (6 -9) , each of which is thought to possess varying abilities to activate downstream signaling pathways (10 -14) . It is now generally accepted that the ability of an agonist to induce a receptor-mediated response (i.e. efficacy) can vary across the distinct signaling pathways emanating from a single GPCR, a phenomenon conceptualized within the frameworks of biased agonism (15) and "functional selectivity" (16) . In the limit case, completely biased agonists antagonize one arm of signaling (e.g. G protein-mediated) while simultaneously activating another (e.g. ␤arr-mediated). Peptide analogs of angiotensin II (AngII), which serves as the endogenous agonist for the angiotensin II type 1 receptor (AT 1 R), represent some of the most striking examples of completely biased agonists to date (17) . Interestingly, some of these ␤arr-biased ligands (e.g. TRV120023 and TRV120027) exhibit unique beneficial properties in vivo, which are consistent with their complete bias for ␤arr2 versus G q -mediated signaling in cellular assays (18 -21) . More generally, biased GPCR agonists have immense therapeutic potential by virtue of their abilities to favor signaling pathways required for therapeutic effects over those responsible for deleterious side effects (22, 23) .
Despite this, the molecular mechanism(s) by which biased agonists selectively engage distinct signaling pathways such as those mediated by G proteins and ␤arrs remain elusive. This is due in large part to the complexities of tissue and cellular assays that alter the apparent efficacies of agonists and confound their accurate quantification (17, 24) . Various qualitative and quantitative methods have emerged to overcome issues arising from differences in receptor density, the relative stoichiometry of signaling elements, and receptor coupling efficiencies. These include calculating reversals in the rank order of potencies and efficacies (25, 26) , making "equimolar" (27) and "equiactive" comparisons (28) , and estimating coupling efficiency (17) and transduction coefficients (29) using the operational model (30) . However, the best approach remains controversial (31, 32) . Alternatively, defining efficacy in precise chemical terms would bypass these limitations and permit the accurate quantitation of ligand efficacy at distinct transducer pathways in vitro, thereby facilitating investigation of the molecular basis of biased agonism. Accordingly, we developed a cell-free approach to quantify the molecular efficacies of balanced and biased AT 1 R agonists for activating G protein and ␤arr pathways (i.e. "transducerspecific molecular efficacies"). This allowed us to test the hypothesis that biased agonism arises from differences in ligand-receptor-transducer ternary complex (LRT) interactions. Our approach was based on the following fundamental tenets: 1) GPCRs are prototypic allosteric proteins (33, 34) ; 2) efficacy, as it is conceived to reside within the LRT ternary complex (35, 36) , can be defined in precise chemical terms as the allosteric effect that a receptor-bound ligand exerts on the coupling and consequent activation of a signal transduction protein (i.e. molecular efficacy); 3) the allosteric effect exerted by a given agonist-receptor interaction at one transducer protein is not of equal magnitude to that at another transducer, suggesting that molecular efficacies can be biased for different signaling pathways (34, 37) . Based on these assumptions we equated shifts in the binding affinities (i.e. K Lo /K Hi ) of ligands at AT 1 R-G q and AT 1 R-␤arr2 fusion proteins with their molecular efficacies for activating G q and ␤arr2, respectively. The transducer-specific molecular effi-cacies reported here represent the first attempt to quantify the thermodynamic driving forces underlying differences in ligand efficacy between transducers.
EXPERIMENTAL PROCEDURES

Generation of AT 1 R-G q and AT 1 R-␤arr2 Fusion Constructs-
AT 1 R-G q and AT 1 R-␤arr2 fusion proteins containing a cleavable N-terminal Hemophilus influenza hemagglutinin membrane insertion signal sequence and N-terminal FLAG epitope tag were generated via overlapping PCR. For the AT 1 R-G q fusion protein, PCR amplicons of full-length human AT 1 R cDNA (NM_009585) and full-length human G q cDNA (NM_002072) were digested with DpnI, gel-purified, and combined at a ratio of 1:1. The mixture was digested with T4 DNA polymerase and quenched with dCTP before ligation with T7 DNA ligase. A 17-amino acid linker (GGGGSAEAAAKAGGG-GSM) was subsequently introduced via insertional mutagenesis (Stratagene, La Jolla, CA). For the AT 1 R-␤arr2 fusion protein, PCR amplicons of full-length human AT 1 R cDNA and fulllength rat ␤arr2 cDNA (NM_012911) were ligated according to the above procedure. A stop codon was subsequently inserted at amino acid 395 to generate a truncated, phosphorylationindependent ␤arr2. The resulting AT 1 R (1152 bp, 44 kDa), AT 1 R-G q (2280 bp, 87 kDa), and AT 1 R-␤arr2 (2334 bp, 88 kDa) constructs were subcloned into pcDNA3 and sequenced (Duke DNA Analysis Facility, Durham, NC) before use.
Cell Culture-HEK 293 cells were cultured at 37°C in a humidified environment (5% CO 2 ) using standard minimum Eagle's growth medium supplemented with 10% FBS, 100 units/ml penicillin, and 100 g/ml streptomycin. Monoclonal cell lines stably expressing high levels of AT 1 R (clone #15), AT 1 R-G q (clone #15), or AT 1 R-␤arr2 (clone #23) were selected from a pool of HEK 293 cells transiently transfected with 2 g of AT 1 R, AT 1 R-G q , or AT 1 R-␤arr2 cDNA. Selection was initiated and maintained with 500 g/ml G418. HEK 293 cells stably expressing the human AT 1 R were cultured for inositol monophosphate (IP 1 ) accumulation assays as previously described (18) . U2OS cells were cultured for internalization assays as described by the manufacturer (DiscoveRx, Fremont, CA).
Immunoprecipitation and Immunoblotting-AT 1 R, AT 1 R-G q , and AT 1 R-␤arr2 receptor proteins were immunoprecipitated from stable cell lines using standard procedures. Briefly, cells were solubilized in cold lysis buffer (5 mM HEPES, pH 7.5, 250 mM NaCl, 0.5% Nonidet P-40, 10% glycerol, 2 mM EDTA, 0.01% n-dodecyl-␤-D-maltoside, and EDTA-free protease inhibitor mixture). After centrifugation, the cleared lysate was incubated overnight at 4°C with anti-M2 FLAG-agarose beads. Receptors bound to beads were washed extensively with cold lysis buffer, deglycosylated with peptide N-glycosidase F, and eluted with lysis buffer containing 400 M FLAG peptide (Sigma). Immunoprecipitated receptors were resolved on 4 -20% SDS-PAGE gels and immunoblotted using standard procedures. Immunoreactive bands representing the AT 1 R (polyclonal ␣-FLAG, Sigma), the AT 1 R-G q fusion protein (polyclonal ␣-G q , Santa Cruz Biotechnology, Inc., Dallas, TX), and the AT 1 R-␤arr2 fusion protein (polyclonal ␣-␤arr2, A1CT (38)) were visualized using GeneSnap Imaging software (Syngene, Frederick, MD).
Membrane Purification-To quantify G q molecular efficacy, a single large batch of purified membrane was prepared from AT 1 R (clone #15)-or AT 1 R-G q (clone #15)-expressing cells. High levels of receptor expression were achieved by co-transfecting stable lines (FuGENE 6, Roche Applied Science) with additional receptor cDNA and the pAdvantage vector (ratio of 4:1, Promega, Madison, WI) as well as culturing in the presence of 2% DMSO. Cells were harvested in cold wash buffer (20 mM Tris-HCl and 150 mM NaCl, pH 7.4) and Dounce-homogenized (100 strokes) in cold homogenization buffer (20 mM Tris-HCl and EDTA-free protease inhibitor mixture, pH 7.4). Following differential centrifugation, the P2 microsomal membrane fraction was resuspended in cold buffer (50 mM Tris-HCl, protease inhibitor mixture, 150 mM NaCl, 12.5 mM MgCl 2 , 0.2% BSA, and 10% glycerol, pH 7.4), aliquoted, and stored at Ϫ80°C until use. To quantify ␤arr2 molecular efficacy, a modified version of the aforementioned procedure was used to prepare a single large batch of purified membrane from AT 1 R (clone #15)-or AT 1 R-␤arr2 (clone #23)-expressing cells. Specifically, cells were co-transfected with a membrane-targeted GRK2 mutant (i.e. CAAX GRK2) to promote receptor phosphorylation and ␤arr2 coupling (39) . Consequently, phosphatase inhibitors (5 nM microcystin LF, 10 nM calyculin A, 10 mM sodium fluoride, 1 mM tetrasodium pyrophosphate , and 1 mM ␤-glycerophosphate) were added to homogenization and resuspension buffers.
Ligands-Angiotensin II was synthesized by GenScript USA Inc. (Piscataway, NJ). TRV120023, TRV120026, TRV120034,  TRV120044, TRV120045, TRV120055, and TRV120056 Radioligand Binding Assays-Competition radioligand binding assays using unfused and transducer-fused AT 1 R-expressing membranes were conducted in parallel to facilitate rigorous analysis (see "Experimental Procedures"). Competition binding assays measuring G q molecular efficacy were performed in a G q assay buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 12.5 mM MgCl 2 , and 0.2% BSA) containing 50 pM 125 I-Sar 1 ,Ile 8 -AngII, AT 1 R (0.5 g) or AT 1 R-G q (0.25 g) membranes, and a serial dilution of test ligand. Binding assays measuring ␤arr2 molecular efficacy were performed in ␤arr2 assay buffer (50 mM Tris-HCl, pH 7.4, 50 mM potassium acetate, 150 mM NaCl, 5 mM MgCl 2 , and 0.2% BSA) containing 50 pM 125 I-Sar 1 ,Ile 8 -AngII, AT 1 R ϩ CAAX GRK2 (1 g) or AT 1 R-␤arr2 ϩ CAAX GRK2 (0.4 g) membranes, and a serial dilution of test ligand. Nonspecific binding was determined in the presence of 10 M telmisartan, whereas total binding was determined in the absence of a competitor. To ensure accurate low affinity determination, binding assays on unfused AT 1 R membranes included a non-hydrolyzable GTP analog 5Ј-guanylyl imidodiphosphate (GPP(NH)P) at 1 M for G q assay and 100 M for ␤arr2 assay. After a 1.5-h incubation at 25°C, bound radioactivity was collected on 0.3% polyethyleneimine-treated GF/C filters using cold G q wash buffer (50 mM Tris-HCl, pH 7.4) or cold ␤arr2 wash buffer (50 mM Tris-HCl, pH 7.4, and 50 mM potassium acetate). Bound radioactivity was quantified on a Packard Cobra gamma counter (GMI, Ramsey, MN). Saturation binding assays were performed on AT 1 R-G q and AT 1 R-␤arr2 membranes as described above except that serial dilutions of 125 I-AngII (5 pM to 1 nM) and 125 I-Sar 1 ,Ile 8 -AngII (5 pM to 2 nM) were used to label transducer-coupled and total AT 1 R populations, respectively. IP 1 Accumulation-IP 1 accumulation was measured using the IP-One Tb HTRF kit (Cisbio, Bedford, MA) as described previously (18) .
AT 1 R Internalization Assays-␤arr-dependent AT 1 R internalization was measured using the activated endocytosis assay (DiscoveRx, Fremont, CA). Briefly, the human AT 1 R was transiently expressed in U2OS cells stably expressing an Enzyme Acceptor-tagged ␤arr2 and an endosome-localized ProLink tag. Cells (20,000 cells/well) were incubated in 96-well plates for 24 h and stimulated with test ligand (100 M to 0.1 nM) for 30 min or 3 h at 37°C. AT 1 R internalization was detected as luminescence resulting from the complementation of ␤-galactosidase fragments (Enzyme Acceptor and ProLink) within endosomes. Luminescence was detected on a NOVOstar plate reader (BMG Labtech Inc., Cary, NC) using the PathHunter Detection kit (DiscoveRx, Fremont, CA).
␤arr2 Recruitment Assays-The PathHunter ␤arr assay from DiscoveRx (Fremont, CA) measured recruitment of ␤arr2 to the AT 1 R for cellular bias calculations as described previously (17, 18) . ERK1/2 Phosphorylation Assays-ERK1/2 phosphorylation was measured using the Cellul'erk HTRF kit (Cisbio, Bedford, MA). HEK 293 cells (50,000 cells/well) transiently expressing the unfused AT 1 R, AT 1 R-G q , or AT 1 R-␤arr2 fusion proteins were stimulated with 1 M AngII for 10 min at 37°C. Plates were read on a PheraStar reader using a time-resolved fluorescence ratio of 665 nm/615 nm. ERK1/2 phosphorylation was reported as -fold over base-line response.
Quantification of Ligand-transducer Free-energy Coupling-The simplest quantity describing the differential efficacy of ligands at the molecular level is the ligand-induced allosteric effect that governs receptor coupling to the transduction protein (i.e. molecular efficacy; Ref. 36 ). According to linkage thermodynamics (40, 41) , the simultaneous binding of ligand and transduction protein to distinct sites on a receptor permits measurement of the allosteric coupling (i.e. ␣) between agonist and transduction protein by calculating the ratio of "unconditional" and "conditional" binding constants,
where K L or K T are the dissociation constants for the ligand (L) or the transducer (T) when each binds to the receptor in the absence of the other, and K L(T) or K T(L) are the dissociation constants when each binds to a receptor already saturated by the other. Because ␣ itself represents an equilibrium constant (i.e. describing the disproportionation reaction:
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where R ϭ the ideal gas constant, and T ϭ thermodynamic temperature. Thus, ␣ provides an overall physical measure of agonist molecular efficacy independent of the underlying microscopic mechanisms. It was on this theoretical background that the ternary complex model (TCM) of receptor-G protein interaction was originally proposed to explain the correlation between GTP effects on ligand binding and ligand efficacy (35) .
It is also clear that this measurement of ␣ or molecular efficacy directly leads to an accurate assessment of the molecular source of ligand bias. In fact, if the allosteric coupling of an agonist can be determined at receptor ternary complexes consisting of two different transducers (T1 and T2), molecular bias is defined as the ratio,
A molecular bias of ≈1 indicates a balanced agonist, whereas values above or below unity would indicate that the agonist has greater efficacy for the first or the second transducer, respectively.
According to the TCM, approximate values of ligand efficacies can be determined by measuring the GTP-induced shift of agonist affinities in different transduction proteins. However, this approach cannot be used for transduction proteins such as arrestins, which are neither resident in the membrane nor regulated by guanine nucleotides. To bypass the problem, we adopted an alternative strategy. As shown previously, chimeric proteins consisting of receptors fused to different transduction proteins are functionally coupled and maintain the same efficacy profiles of the native receptor (42) . Under such conditions, it is assumed that the presence of a covalently tethered transducer on the receptor can emulate the situation in which a transduction protein is expressed in the membrane at large stoichiometric excess over receptor. Thus, the shift in agonist binding affinity between free and transducer-linked receptors can assess the free-energy coupling of that agonist for that transducer as presented in Equation 2. Here, comparing agonist allosteric effects on AT 1 R fused to G q or to ␤arr2 permits us to evaluate the molecular bias of AT 1 R agonists for the two transduction proteins.
In the case of GPCRs where agonist dissociation constants are typically determined from competition curves using a radioligand, the ratio of agonist binding constants is
where K L and K L(T) are the respective agonist binding constants from competition curves in free and transducer-fused receptor, and the starred parameters, [L*], K L *, and ␣*, indicate the concentration, dissociation constant, and the coupling constant of the radioligand, respectively. If the radiotracer is a neutral antagonist (i.e. ␣* ϭ 1), the ratio of competition binding constants (commonly referred to as K Lo /K Hi ) equals the agonist molecular efficacy, ␣. Moreover, the effect of small deviations in radioligand efficacy from unity (e.g. 2 Ն ␣* Ն 0.5) are mini-mized if the radioligand concentration is below its dissociation constant.
Curve Fitting and Computation of '␣'-Transducer-fused GPCRs in membranes display biphasic competition curves (42) . This is typical of a situation in which there is roughly an equimolar mix of binding sites having high and lower affinity for the agonist. Various factors (42) , including those related to the heterogeneity of plasma membrane topology and/or to the supramolecular organization of receptor/transduction proteins, could be responsible for the apparent sequestration of a large fraction of receptor in an uncoupled, low affinity form. A pragmatic solution is to fit the data with a two-site binding model to deconvolute the high affinity component from biphasic competition curves, calculating ␣ values under the constraint that the fraction of coupled receptor is a constant shared by all ligands. Such a curve-fitting procedure, however, can only work for ligands with high ␣ values, because as the ratio of dissociation constants drops close to 10, two-site binding isotherms become indistinguishable from a one-site binding curve with slope factor Ͻ Ͻ1.
To address the inaccuracy with which ␣ is computed from weakly shifted binding curves, we adopted a two-step fitting protocol (using the Solver Add-in for Excel, Microsoft, Redmond, WA). First, all the pairs of competition binding curves obtained in membranes expressing transducer-fused or unfused receptors for each ligand were fitted using the singlesite binding model,
where B is radioligand binding in the absence (B 0 ) and presence (B n ) of saturating unlabeled ligand, K 0.5 is the concentration of agonist at half-maximal binding inhibition, [A] T is the total concentration of competing ligand, and s is the slope factor at K 0.5 . Using the best-fitting parameters computed above, the experimental data points of each pair of curves were rescaled on both the y axis, as fractional binding (i.e. B/B 0 ϭ (B Ϫ B n )/(B 0 Ϫ B n )), and the x axis, as log-unit change about the K 0.5 value of the unfused receptor (i.e. ⌬x ϭ log[A] T Ϫ log K 0.5-unfused ). Effectively, this normalization subtracts from the data the individual differences in K d values across ligands without altering the shape of the binding isotherms. As a result, all ligand curves can be re-fitted simultaneously in the subsequent analysis using a reduced set of unknown parameters.
In the second step, all normalized competition curves obtained at both transducer fusion proteins (along with the corresponding unfused receptor controls) were globally fitted using the following two-site binding function,
where F is the fraction of high affinity binding (i.e. fraction of transducer-coupled receptor, F ϭ 0 for the unfused receptor), and s1 and s2 are the slope factors of the two binding components. Simultaneous fitting of competition binding curves for all 10 ligands at both transducer fusion proteins (together with the matching curves of the unfused receptor) was accomplished by sharing the parameter F among all ligands. Of the two slope factors, s1 was set ϭ 1 for all ligands, whereas s2 was a freely adjustable fitting parameter. Separate tests in which s1 was varied for each ligand showed that the values of this parameter have a negligible influence on the overall goodness of fit and the final ␣ values, as determined by F-tests based on the extra sum of squares principle (43) . The validity of the fundamental assumption that F can be shared across the two fusion proteins was statistically and experimentally verified. First, we found that in three independent experiments the fractions of coupled receptors were not significantly different when the sets of binding curves obtained in the two fusion proteins were fitted separately (means Ϯ S.D. were 40 Ϯ 4% at AT 1 R-G q and 41 Ϯ 5% at AT 1 R-␤arr2, p ϭ 0.35 by F-test). Second, direct binding studies with 125 I-AngII and 125 I-Sar 1 ,Ile 8 -AngII to measure the maximal fraction of high affinity binding accessible to the agonist indicated no significant difference between membranes expressing AT 1 R-G q or AT 1 R-␤arr2 (means Ϯ S.E. were 49 Ϯ 2% at AT 1 R-G q and 48 Ϯ 5% at AT 1 R-␤arr2; n ϭ 3; p ϭ 0.78 by F-test).
Calculating the Area between Two Binding Curves (⌬ Integral)-To verify that the above assumptions (particularly the sharing of the parameter F across ligands) do not introduce a systematic error in the assessment of ligand ␣ values, we also used a model-free approach to quantify the shift in agonist binding upon transducer coupling. For each agonist we measured the area of the region bounded by the unfused and transducer-fused displacement curves. Ligand binding curves from paired experiments on unfused and transducer-fused AT 1 R were normalized as described above and numerically integrated with respect to the same range of ⌬x units (Ϫ5,3). The area of the bounded region was calculated by taking the difference of the two integral values (unfused minus transducer-fused AT 1 R, ⌬ integral).
Data Analysis-Functional experiments were analyzed using the nonlinear iterative curve-fitting computer program Graphpad Prism 5 (GraphPad Software Inc., La Jolla, CA). AT 1 R internalization and IP 1 accumulation data were fit to a three-parameter log concentration-response curve to generate potency (log EC 50 ) and maximal response (E max ) values. To account for differences in assay amplification, efficacy values for IP 1 accumulation (log IP1 accumulation ) and AT 1 R internalization (log internalization ) were calculated according to the procedure of Rajagopal et al. (17) . The resulting values are a true estimation of ligand efficacy given the constraint imposed by setting the low affinity value constant. Briefly, published (17) and unpublished data were fit to the operational model of Black and Leff (30) , setting the Log K D of each ligand equal to its low affinity log K i determined at the unfused AT 1 R. Bias factors (␤) were calculated for published (17) and unpublished data according to the operational approach of Rajagopal et al. (17) . Molecular bias was calculated from transducer-specific molecular efficacies using Equation 3 (see "Quantification of Ligandtransducer Free-energy Coupling" under "Experimental Procedures"). Radioligand binding experiments, except those used to quantify molecular efficacy (see "Curve Fitting and Computation of ␣" under "Experimental Procedures"), were analyzed using GraphPad Prism 5.
Statistics-Standard statistical tests (i.e. two-tailed Pearson correlation, one-way ANOVA, two-way ANOVA, and F tests) were performed using the GraphPad Prism package. A threshold significance level of p Ͻ 0.05 was used for all tests.
RESULTS
Quantification of the Transducer-specific Molecular Efficacies of GPCR Agonists in Vitro-
To quantify the transducerspecific molecular efficacies of different GPCR ligands and investigate the molecular basis of biased agonism, we developed a cell-free approach that discriminates between the allosteric effects that different transducers exert upon the binding of a ligand to a GPCR (see "Experimental Procedures" for a detailed discussion). As originally theorized in the TCM (35, 36) , the molecular efficacy of an agonist is quantified by the coupling free-energy ␣ that can be measured from the shift in apparent ligand affinity (i.e. K Lo /K Hi ), which results from the formation of the receptor-transducer protein complex. This leftward shift represents the ratio of the dissociation constant of the ligand for the uncoupled receptor (i.e. low affinity, K Lo ) to that for the transducer-coupled receptor (i.e. high affinity, K Hi ). A graphic illustration of ␣ quantification is shown in Fig. 1A . ). Relative to the low affinity value (K Lo ) that is shared between unfused and transducer-fused GPCRs, the magnitude of the leftward shift to a higher affinity (K Hi ) at the GPCR-transducer fusion protein equals the molecular efficacy for activating the fused transducer (i.e. K Lo /K Hi ϭ ␣ T ). Competition binding isotherms were generated in Prism 5.0 (Graphpad) by fitting simulated data to onesite (fraction coupled ϭ 0) and two-site (fraction coupled ϭ 0.5) competition binding models. The highlighted area between the curves (gray) represents ⌬ integral, which is a model-free quantification of molecular efficacy (see "Calculating the Area between Two Binding Curves" under "Experimental Procedures"). B, the affinity shift of a balanced ligand is predicted to be of similar magnitude across GPCR-transducer fusion proteins (␣ A ϭ 220 and ␣ B ϭ 300). C, the affinity shift of a biased ligand is predicted to be of greater magnitude at one GPCRtransducer fusion protein over another (␣ A ϭ 2.2 and ␣ B ϭ 300). D, the competition binding isotherms of an antagonist are unaffected by transducer coupling, with affinity shifts approaching unity at both GPCR-transducer fusion proteins (␣ A ϭ 2.2 and ␣ B ϭ 1.5).
We accomplished this for G protein and ␤arr signaling pathways by exploiting the unique properties of genetically encoded fusion constructs containing a GPCR and a C-terminally fused G q or ␤arr2. More specifically, we chose the AT 1 R fused to either G q or ␤arr2 as our model system based on the recent identification of a large panel of G q -and ␤arr2-biased AT 1 R agonists (17) . To accurately quantify K Lo /K Hi shifts at AT 1 Rtransducer fusion proteins, we adopted two complementary but independent approaches. In the first approach we computed K Lo /K Hi or ␣ by fitting the curves with a two-site binding model, which assumes the existence of two fractions of the same receptor, only one of which can couple to the signal transduction protein (see "Curve Fitting and Computation of ␣" under "Experimental Procedures" for a detailed discussion). Note that ␣ here represents the overall amount of free-energy change involved in the conformational perturbation that produces the active LRT ternary complex (36) . Thus, the difference in ␣ values of an agonist for two transducers quantifies the extent of bias of that agonist on the free-energy scale. Graphic illustrations of the predicted differences between balanced agonists, biased agonists, and antagonists are shown in Fig. 1, B, C, and D, respectively.
The second approach was derived from the empirical observation that transducer coupling to a receptor results in a leftward translation in agonist competition curves (i.e. to a higher affinity) relative to the uncoupled receptor (35, 44) . Thus, we computed the area between the unfused and transducer-fused competition curves to quantify the transducer effect, taking advantage of the fact that all measurements were performed in parallel throughout the study. This is represented by the shaded region in Fig. 1A , hereafter referred to as ⌬ integral (see "Calculating the Area between Two Binding Curves" under "Experimental Procedures"). Although this quantity provides information equivalent to the K Lo /K Hi ratio, it was obtained from a model-free approach and is thus independent of the assumptions used for the computation of ␣.
Generation and Validation of AT 1 R-G q and AT 1 R-␤arr2 Fusion Proteins-We generated functional AT 1 R-G q and AT 1 R-␤arr2 fusion proteins to quantify transducer-specific molecular efficacies in vitro. As detailed in Fig. 2A , the AT 1 R-G q fusion protein consisted of the human G q protein fused via a linker to the extreme C terminus of the human AT 1 R, and the AT 1 R-␤arr2 fusion protein consisted of the truncated rat ␤arr2 fused to the extreme C terminus of the human AT 1 R. Control immunoblots showed that, relative to the unfused AT 1 R, both AT 1 R-G q and AT 1 R-␤arr2 constructs were stably overexpressed as intact fusion proteins in HEK 293 cell membranes (arrows, Fig. 2, B-D) . Saturation binding analysis of the same purified membranes confirmed that unfused and transducer-fused constructs were indeed overexpressed (B max Ϯ S.E. was 7.1 Ϯ 0.1pmol/mg for AT 1 R membranes, 15.1 Ϯ 0.2 pmol/mg for AT 1 R-G q membranes, and 10.7 Ϯ 0.3 pmol/mg for AT 1 R-␤arr2 membranes; n ϭ 3) and properly folded (K d Ϯ S.E. for antagonist 125 I-Sar 1 ,Ile 8 -AngII binding to the AT 1 R was 212 Ϯ 12 pM, to AT 1 R-G q was 242 Ϯ 10 pM, and to the AT 1 R-␤arr2 was 271 Ϯ 28 pM; n ϭ 3) ( Fig. 2E) .
Experiments assessing the ability for the endogenous agonist AngII to compete with high affinity against the antagonist radioligand 125 I-Sar 1 ,Ile 8 -AngII were used to verify the functionality of AT 1 R-G q and AT 1 R-␤arr2 fusion proteins. Consistent with functional coupling between the AT 1 R and its fused G q (Fig. 1A) , high affinity AngII binding at the AT 1 R-G q fusion protein was blocked by the non-hydrolyzable GTP analog GPP(NH)P (Fig. 2F) . Conversely, high affinity AngII binding remained largely intact at the AT 1 R-␤arr2 fusion protein in the presence of high concentrations of GPP(NH)P, indicative of functional coupling between the AT 1 R and its fused ␤arr2 (Fig.  2G) . We further confirmed that each fusion protein was competent to signal by testing the ability of AngII to induce ERK1/2 phosphorylation in HEK 293 cells transfected with AT 1 R, AT 1 R-G q , or AT 1 R-␤arr2. Consistent with normal AT 1 R function (45), a 10-min treatment with 1 M AngII resulted in significant increases in ERK1/2 phosphorylation that were similar across unfused and transducer-fused AT 1 R cell lines (-fold increase Ϯ S.E. was 1.95 Ϯ 0.17 for AT 1 R, 1.80 Ϯ 0.17 for AT 1 R-G q , and 1.5 Ϯ 0.03 for AT 1 R-␤arr2; n ϭ 4; p Ͻ 0.05 by one-way ANOVA comparing responses to AngII-stimulated control cells). Untransfected HEK 293 cells were unresponsive to AngII (-fold increase Ϯ S.E. was 0.93 Ϯ 0.03; n ϭ 4), confirming that ERK1/2 phosphorylation was mediated exclusively by exogenously expressed AT 1 Rs.
Quantifying the Molecular Efficacies of AT 1 R Ligands at Two Distinct Transducer Pathways in Vitro-The allosteric nature of ligand efficacy permitted us to equate shifts in ligand binding affinities (i.e. K Lo /K Hi ) at AT 1 R-G q and AT 1 R-␤arr2 fusion proteins with their molecular efficacies for activating G q and ␤arr2, respectively (see "Experimental Procedures" for a detailed discussion). To demonstrate this and ultimately investigate the molecular basis of biased agonism at the AT 1 R, we quantified the molecular efficacies of AT 1 R ligands which exhibit a wide range of cellular efficacies for G q and ␤arr2 signaling. These included: 1) the balanced, endogenous full agonist AngII (17); 2) the ␤arr2-biased agonists SII, TRV120023, TRV120026, TRV120034, TRV120044, and TRV120045 (17, 18, 46) ; 3) the G q -biased agonists TRV120055 and TRV120056 (17); 4) the antagonist telmisartan (47) .
In close agreement with previous studies assessing agonist binding at GPCR-transducer fusions in cell membranes (42), a fraction (ϳ40%) of receptors was available for formation of high affinity ternary complexes containing G q or ␤arr2. Qualitatively, the coupling of G q or ␤arr2 to the AT 1 R had wide-ranging effects on ligand affinities that could be classified according to their reported activation of G q and ␤arr2 in cells (Fig. 3) .
Quantification of these affinity shifts as ␣, free-energy (i.e. ⌬⌬G), or ⌬ integral values revealed a wide range of molecular efficacies for activating G q and ␤arr2 signaling pathways (Table  1) . First, consistent with the prediction made for balanced activation of two distinct signaling pathways (Fig. 1B) , AngII pos-sessed molecular efficacies of roughly equal magnitude for both transducers (Fig. 3A) . Second, consistent with the prediction made for biased activation of ␤arr2 over G q (Fig. 1C) , the molecular efficacies of previously identified ␤arr2-biased agonists SII, TRV120023, TRV120026, TRV120034, TRV120044, and TRV120045 were larger at the AT 1 R-␤arr2 fusion protein relative to the AT 1 R-G q fusion protein (Fig. 3B ). In fact, the G q molecular efficacies of completely ␤arr2-biased ligands such as TRV120026, TRV120034, and TRV120044 were small and approached that of the antagonist telmisartan. This is in good agreement with the ability of the structurally related ␤arr2biased peptide TRV120027 to function as an antagonist of G q signaling in cells (18) . Third, consistent with the prediction made for biased activation of G q over ␤arr2 (Fig. 1C) , the molecular efficacies of G q -biased agonists TRV120055 and TRV120056 were 10-fold larger at the AT 1 R-G q fusion protein compared with the AT 1 R-␤arr2 fusion protein (Fig. 3C) . The G q molecular efficacies of TRV120055 and TRV120056 were, in fact, the largest of any ligand tested (Table 1) . This is consistent with their extremely high efficacy values for activating G q in cells (17) . Fourth, as predicted ( Fig. 1D) , the antagonist telmisartan lacked detectable molecular efficacy at either transducer (Fig. 3D) .
We also observed that the computation of ⌬ integral values yielded estimates that could explain 99% of the variance in molecular efficacies calculated from K Lo /K Hi values in vitro (G q r 2 ϭ 0.9911, p Ͻ 0.0001 and ␤arr2 r 2 ϭ 0.9942, p Ͻ 0.0001 by two-tailed Pearson correlation) (Fig. 4 ). This strong agreement in molecular efficacies using two independent analytical approaches highlights the accuracy and robustness of our curve-fitting procedure.
Investigating the Relationship between Apparent Ligand Efficacies Calculated in Cellular Assays and Molecular Efficacies
Calculated in Vitro-To test the TCM prediction that freeenergy values account for variations in biological effects, we determined if the efficacies for activating G q and ␤arr2 in cells (i.e. log according to Ref. 17) correlated with molecular efficacies calculated at fusion proteins in vitro (i.e. log ␣). Consistent with TCM predictions, the efficacies of AT 1 R ligands for activating G q and promoting IP 1 accumulation in cells (Fig. 5A ) were significantly correlated with their molecular efficacies calculated at the AT 1 R-G q fusion protein (r 2 ϭ 0.9189, p ϭ 0.0007 by two-tailed Pearson correlation; Fig. 5B ).
A similar relationship was observed for ␤arr2. Efficacies corresponding to the abilities of AngII, TRV120055, TRV120056, TRV120023, and SII to promote AT 1 R internalization in cells (i.e. a classic ␤arr-dependent process (4); Fig. 5C ) were significantly correlated with their ␤arr2 molecular efficacies calculated at the AT 1 R-␤arr2 fusion protein (r 2 ϭ 0.7909, p ϭ 0.0435 by two-tailed Pearson correlation; Fig. 5D ). Because of the low level of amplification in the internalization assay, strong agreement was also observed between maximal cellular responses (E max ) and ␤arr2 molecular efficacies (r 2 ϭ 0.9140, p ϭ 0.011 by two-tailed Pearson correlation). Rank orders of potency and efficacy (calculated as and E max values) were conserved in a shorter internalization assay (30 min), alleviating concerns that cellular contributions over the 3-h incubation period confounded internalization measurements.
Analysis of Biased Molecular Efficacy at the AT 1 R-Strong
correlations between transducer-specific molecular efficacies and the biased activation of G q or ␤arr2 signaling pathways in cells (Fig. 5, B and D) suggested that biased AT 1 R agonists possess biased molecular efficacies. To determine if biased agonism arises from differences in LRT ternary complex interactions, we computed molecular bias as the difference in log ␣ values across G q and ␤arr2 transducers (i.e. log(␣ Gq /␣ ␤arr2 )). This index resulted in positive values for G q -biased agonists (blue) and negative values for ␤arr2-biased agonists (red). As shown in Fig. 6A , our ligand panel revealed striking examples of diametrically opposite biased molecular efficacies. Specifically, the peptides TRV120056 and TRV120055 showed a large degree of bias for G q , whereas TRV120045, TRV120034, TRV120023, TRV120044, and TRV120026 displayed an equally large, yet opposite bias for ␤arr2. A lower level of ␤arr2 bias was observed for SII, whereas the "balanced" agonist AII and antagonist telmisartan displayed small levels of bias toward G q . Note that despite the small bias factor, the ␤arr2 bias of SII was significantly different from that of the antagonist telmisartan, which lacked molecular efficacy at either transducer (p Ͻ 0.05 by one-way ANOVA and Tukey-Kramer post-tests). By this criterion, AngII appeared balanced (p Ͼ 0.05 by one-way ANOVA and Tukey-Kramer post tests).
A test of our ability to identify biologically relevant bias at the molecular level is presented in Fig. 6B . We found that biased molecular efficacies were strongly correlated with bias factors calculated in cells using an operational model of agonism (17) (r 2 ϭ 0.8605, p ϭ 0.003 by two-tailed Pearson correlation). This supports a mechanism whereby biased molecular efficacies generate signaling bias in cellular assays.
To understand how transducer bias might arise for each ligand, we plotted molecular efficacy (i.e. log ␣ Gq and log ␣ ␤arr2 ) as a function of the molecular bias between these transducers (i.e. log(␣ Gq /␣ ␤arr2 )). Driven by their transducer preferences, ␤arr2-biased ligands clustered in the lower left quadrant, whereas G q -biased ligands clustered in the upper right quadrant (Fig. 6C) . The extent to which these ligands were biased was represented not only by their displacement from 0 along the x axis but also by the vertical distance between G q and ␤arr2 molecular efficacies. Trends in the vertical distances between transducers for each ligand revealed that the mechanism producing ␤arr2 bias differed from that generating G q bias. For ␤arr2 bias, there was a loss in G q molecular efficacy that was 
. Shifts in binding affinities at AT 1 R-G q and AT 1 R-␤arr2 fusion proteins quantify the transducer-specific molecular efficacies of a series of AT 1 R ligands.
Ligands were grouped according to their previously reported efficacies in cells (17, 18, 46, 47) . Plotted for each ligand are 125 I-Sar 1 ,Ile 8 -AngII competition radioligand binding isotherms performed on purified HEK 293 cell membranes overexpressing the unfused AT 1 R (ⅷ, f), the AT 1 R-G q fusion protein (E), or the AT 1 R-␤arr2 fusion protein (Ⅺ). Both the x axis and y axis were normalized for simultaneous nonlinear regression curve fitting (see "Curve Fitting and Computation of ␣" under "Experimental Procedures"), yielding an average value of 40% for AT 1 R in the high affinity state. The plotted isotherms represent the global fits of at least three independent experiments, and data points represent the mean of one representative experiment performed in duplicate. The highlighted area between the curves (⌬ integral, see "Calculating the Area between Two Binding Curves" under "Experimental Procedures") represents the magnitude of the curve-shift and is proportional to the molecular efficacy for G q (blue) or ␤arr2 (red). A, 125 I-Sar 1 ,Ile 8 -AngII competition binding isotherms for the balanced agonist AngII. Similar shifts were observed at each transducer fusion protein. B, 125 I-Sar 1 ,Ile 8 -AngII competition binding isotherms for the ␤arr2-biased agonists SII, TRV120023, TRV120026, TRV120034, TRV120044, and TRV120045. Shifts at the ␤arr2 fusion protein were larger than those detected at the G q fusion protein. C, 125 I-Sar 1 ,Ile 8 -AngII competition binding isotherms for the G q -biased agonists TRV120055 and TRV120056. Large affinity shifts were observed at the G q fusion protein compared with more modest shifts observed at the ␤arr2 fusion protein. D, 125 I-Sar 1 ,Ile 8 -AngII competition binding isotherms for the antagonist telmisartan. Affinity shifts were undetectable at either transducer fusion protein.
almost exactly compensated by a gain in ␤arr2 efficacy (e.g. see TRV120026). By contrast, G q bias appeared to result from an increase in G q molecular efficacy with no concomitant loss in efficacy for ␤arr2 (e.g. see TRV120056).
DISCUSSION
The molecular mechanism(s) underlying biased agonism remain elusive given the challenges associated with quantifying ligand efficacy in cells (17) . In the alternate approach described here, we bypassed the need for cellular assays by equating shifts in ligand affinity at GPCR-transducer fusion proteins with the activation of different transducers (i.e. transducerspecific molecular efficacies). These studies with balanced and biased AT 1 R agonists provide the most direct test of TCM predictions, revealing that 1) transducer-specific molecular efficacies are strongly correlated with cellular efficacies for activating G q and ␤arr2, and 2) biased agonists possess biased molecular efficacies. These findings support a molecular mechanism whereby differences in the allosteric effect that each ligand propagates to different transducers can generate biased agonism at a GPCR.
Current cell-based approaches measure efficacy, however imperfectly, using complex biological responses as a caliper to indirectly measure the allosteric effect that a ligand exerts on different transducer proteins (37) . By contrast, calculating K Lo / K Hi ratios at different GPCR-transducer fusion proteins (i.e. at different LRT ternary complexes) directly quantifies these allosteric effects. This represents a key technical advance as receptor-transducer interactions occur within covalently tethered scaffolds of defined stoichiometry in fusion proteins, thereby overcoming differences in receptor expression and efficiency of signal transduction (17) , as well as the issue that receptor-transducer interactions differ vastly in timing and cellular location (37) . GPCR-transducer fusion proteins also equalize differences in the unconditional affinity constants that govern the bimolecular interactions between the empty receptor and the two transduction proteins, thus ensuring that the ⌬⌬G values measured for free-energy coupling are not affected by large differences in such constants and accurately represent the net allosteric effect of each ligand. Although it is well known that fused GPCR constructs can interact with endogenous G proteins of the membrane (48), we found that resident G protein had a negligible effect on ␤arr2 coupling (see Fig. 2G ). In addition, because our experimental protocol was based on the comparison of binding curves recorded on transducer-fused and unfused receptor in paired determinations, the potential effects of additional interacting proteins present in the membrane are largely canceled. Thus, the measured K Lo /K Hi ratios (and the closely correlated ⌬ integral values) truly represent the net allosteric effect that each ligand has on the fused transduction protein.
Perhaps the most significant advantage is our ability to accurately measure the thermodynamic driving forces (i.e. free-energy coupling) underlying the stabilization of different active LRT ternary complexes, thereby permitting direct comparisons across transducers. This is made possible because the allosteric effects existing between ligands and transducers are based on exactly the same energy scale.
TABLE 1
Transducer-specific molecular efficacies of AT 1 R ligands for G q and ␤arr2 signaling pathways Therefore, unlike conventional cellular assays, the quantification of transducer-specific molecular efficacies does not rely on normalized data with respect to an arbitrarily chosen reference ligand or with respect to an apparently "maximal" cellular response. Previous work has shown that the K Lo /K Hi ratios of GPCR agonists measured in the presence and absence of GTP are strongly correlated with the efficacy of the ligand in signaling assays (35, 49, 50) . Our data extend such findings by showing that a similar correlation also exists between the ratios of high and low affinity states and agonist efficacy for non-GTP-binding transduction proteins such as ␤arrs. Thus, this study represents the most direct demonstration of the tight correspondence that exists between the empirical concept of ligand efficacy of Stephenson's receptor theory (51) and the allosteric coupling constant defined by the TCM. (17)) and molecular efficacies for activating G q in vitro (log ␣ Gq ). The varying abilities of AngII, TRV120055, TRV120056, SII, TRV120023, TRV120026, and TRV120045 to activate G q in cells were significantly correlated with log ␣ Gq values (r 2 ϭ 0.9189, p ϭ 0.0007 by two-tailed Pearson correlation). Data represent the mean Ϯ S.E. of at least three independent experiments. C, concentrationresponse curves showing the relative abilities of ligands with varying molecular efficacies (i.e. AngII, TRV120055, TRV120056, TRV120023, and SII) to promote ␤arr2-dependent AT 1 R internalization in U2OS cells transiently expressing the human AT 1 R. Data (mean Ϯ S.E. of at least three independent experiments) were normalized to maximal AngII response and analyzed via nonlinear regression curve fitting in Prism 5.0 (Graphpad). Changing the incubation time from 3 h to 30 min at 37°C did not change the rank order of ligand responses. D, correlation analysis of efficacies for promoting ␤arr2-mediated AT 1 R internalization in cells (log internalization (17) ) and molecular efficacies for activating ␤arr2 in vitro (log ␣ ␤arr2 ). The varying abilities of AngII, TRV120055, TRV120056, SII, and TRV120023 to promote AT 1 R internalization in cells were significantly correlated with log ␣ ␤arr2 values (r 2 ϭ 0.7909, p ϭ 0.0435 by two-tailed Pearson correlation). Data represent the mean Ϯ S.E. of at least three independent experiments.
The key observation that a tight correlation exists between the free-energy associated with bias (i.e. biased molecular efficacies) and bias indices measured in cellular assays provides a significant conceptual advance in understanding the molecular mechanism(s) underlying biased agonism. It suggests that the differential activation of G q and ␤arr2 by the biased AT 1 R agonists studied here is accounted for by the difference in allosteric effects that they propagate to G q and ␤arr2. This has important implications with regard to the current conceptualization that biased agonism results from differences arising at two molecular loci, one situated proximally at the level of LRT ternary complex formation (i.e. "ligand" or "efficacy" bias) and the other located distally within the signal amplification machinery (i.e. "system" bias) (52) . Unlike system bias where the process of unequal amplification of distinct signaling pathways yields biased signaling profiles (17) , unequivocal support for the mechanism underlying ligand bias is lacking. This is primarily a technical limitation, reflecting the challenges associated with measuring ligand effects at distinct LRT ternary complexes in cells. Here we directly investigated ligand effects on the formation of different LRT ternary complexes in isolation, observing that both G q and ␤arr2-biased AT 1 R agonists possess biased molecular efficacies. These findings not only provide the most direct support for ligand bias but they also represent the most proximal evidence of biased agonism to date. More broadly, these findings extend our current conceptualization of the LRT ternary complex by merging classic pharmacological theory with the realization that ligand bias is an important feature of many receptor systems.
Within the limits of the small number of peptides investigated, it was apparent that the property of biased agonism at the AT 1 R, especially when directed toward ␤arr2, appears to be quite frequent and robust (Fig. 6A) . The reason for such profound bias is unknown. However, it is interesting to speculate that the tight interactions of ␤arr2 with the AT 1 R, thus making it a class B receptor (53) , may explain the abundance of ␤arr2biased agonists. In support of this, many receptors for which ␤arr-biased ligands have been identified show class B behavior (54, 55) .
On comparing the molecular efficacies of G q and ␤arr2 by scaling their values over the extent of transducer bias (Fig. 6C) , two distinct mechanisms emerged to potentially explain how bias develops at the AT 1 R. The ␤arr2 bias of ligands such as TRV120026 and TRV120044 appeared to result from a reciprocal change in transducer-specific molecular efficacies, where the loss of G q efficacy is associated with an equivalent gain of ␤arr2 efficacy. The G protein bias of ligands such as TRV120055 and TRV120056, instead, occurred as a net FIGURE 6. Investigating biased agonism at the level of the LRT ternary complex. A, bias factors (log(␣ Gq/ ␣ ␤arr2 )) calculated from molecular efficacies at AT 1 R-G q (␣ Gq ) and AT 1 R-␤arr2 (␣ ␤arr2 ) fusion proteins. Positive bias values (blue) denote G q -biased molecular efficacies, whereas negative values (red) denote ␤arr2-biased molecular efficacies. B, correlation analysis of molecular bias values calculated in vitro (Log(␣ Gq/ ␣ ␤arr2 ) relative to AngII) and bias values calculated in cells (␤) according to the operational approach of Rajagopal et al. (17) . Bias at the level of transducer-specific molecular efficacies was significantly correlated with cellular indices of bias (r 2 ϭ 0.8605, p ϭ 0.003 by two-tailed Pearson correlation), suggesting that biased molecular efficacies generate signaling bias in cells. Data represent the mean Ϯ S.E. of at least three independent experiments. C, plotting molecular efficacy at each transducer (log ␣ Gq and log ␣ ␤arr2 ) versus the molecular bias between transducers (log ␣ Gq/ ␣ ␤arr2 )) uncovers a potential mechanism for generating bias at the AT 1 R. ␤arr2-biased ligands (lower left) and G q -biased ligands (upper right) clustered according to their transducer preferences. Trends in the vertical distances between log ␣ Gq (blue) and log ␣ ␤arr2 (red) suggest that ␤arr2 bias arises from a reciprocal loss in G q molecular efficacy and gain in ␤arr2 efficacy, whereas G q bias results from an increase in G q molecular efficacy with no concomitant loss in ␤arr2 efficacy.
increase of efficacy at G q with no loss of ␤arr2 efficacy. This might suggest that within the series of peptides showing enhanced ␤arr2 bias, the change in molecular structure of the ligand alters the overall balance of subsite interactions between receptor and peptide residues. This may result in a progressive shift from interactions that are cooperatively linked to the G protein-binding interface to those that are connected to the ␤arr interface. In contrast, for G q -biased ligands it seems that the change in peptide structure can selectively boost the cooperative effects that favor G q binding without changing the allosteric effects on ␤arr2 binding. Although such speculation is limited by the small number of biased agonists tested, this notion that topographically distinct structural elements move independently to produce bias is consistent with the allosteric nature of GPCRs (56) and the existence of ligand-specific receptor conformations (9) . Direct support for this comes from the observation that functionally similar ligands produce distinct patterns of amino acid side chain reactivity at the ␤2 adrenergic receptor (7) .
A limitation to our approach is the observation that freeenergy values associated with bias represent a small percentage (2-20%) of the overall binding energy of each ligand, potentially making it difficult to accurately determine the bias factors of ligands. Despite this, the weak bias of a ligand like SII was strongly correlated with the biologically derived index of biased efficacy (Fig. 6, A and B) . It is particularly interesting to note that even a free-energy difference between G q and ␤arr2, which is below one RT unit, such as that measured for SII, is nonetheless sufficient to generate a clear impact on biased signaling in cells as documented in several previous studies (45, 46, 57) . This raises the question as to whether differences that entail such very small changes of energy can ever be detected when inspecting the atomic configurations of ligand-bound receptor structures. Although this has yet to be adequately addressed, a recent comparison of x-ray crystal structures of the 5-HT 1B and 5-HT 2B serotonin receptors bound to the biased agonist ergotamine offers initial insight into the structural changes underlying biased agonism (13) .
GRKs are thought to differentially regulate GPCR function by producing distinct patterns of phosphorylation (i.e. phosphorylation "'bar codes"), which alter ␤arr2 conformation and function (58) . A potential limitation is that we did not account for these phosphorylation-driven effects. However, the relationship between ␤arr2 activation in cells and in vitro (Fig. 5D ) suggests that phosphorylation bar codes do not play major roles in the ␤arr2 signaling of the ligands tested here. Nonetheless, GPCR-␤arr2 fusion proteins with defined phosphorylation patterns could represent a powerful approach for quantifying the extent to which phosphorylation bar codes modulate agonist efficacy.
The key observation that biased molecular efficacies strongly correlate with biased agonism in cells (Fig. 6B ) has significant implications for drug discovery. Unlike conventional drugs, which target multiple GPCR signaling pathways, biased agonists potentially represent a novel class of drugs with enhanced efficacy given their abilities to engage specific therapeutic pathways (22, 57) . It is clear that biased agonists with therapeutically relevant signaling profiles at several GPCRs can be developed (57, 59 -62) ; however, the therapeutic potential of biased agonists has yet to be realized in the clinic. In this regard, the concept of biased molecular efficacies is of considerable importance as the bias observed at the level of the LRT ternary complex (i.e. ligand bias) is system-independent and expected to carry over into useful therapeutic bias in various cells and tissues (52) . Indeed, biased ligands at several receptors, which were first characterized in biochemical assays, have shown the cellular and in vivo pharmacology predicted from earlier studies of the underlying G protein and ␤arr pathways (57, 62) . Here we provide direct support for this by showing that the ␤arr2biased molecular efficacy of TRV120023 correlates with both its extreme ␤arr2 bias in cells (17, 18) and ␤arr2-mediated enhancement of cardiac performance in vivo (18, 20, 21) . Moreover, the closely related peptide TRV120027, which exhibits a similar efficacy profile, is now in clinical trials for the treatment of acute heart failure (63) . More broadly, our study suggests that using GPCR-transducer fusion proteins or alternative approaches to quantify ligand molecular efficacy could identify biased agonists with a well defined in vivo pharmacology.
The use of GPCR-transducer fusion proteins has permitted us to accurately quantify transducer-specific molecular efficacies in vitro. When determined for a panel of balanced and biased AT 1 R ligands, it is apparent that ligand efficacy resides at the level of LRT ternary complex interactions. Comparisons across transducers reveal that biased AT 1 R agonists possess biased molecular efficacies, correlating with the bias determined in cellular assays. These findings represent the first quantification of the thermodynamic driving forces underlying differences in ligand efficacy between transducers and suggest that, at least for the AT 1 R, biased agonism can originate at the level of LRT ternary complex interactions. These results have broad implications not only for understanding the molecular mechanisms underlying biased agonism but also for the development of safer and more efficacious therapeutics.
